Elekta AB (publ)

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SRTOY has a market cap of 210.8B. Regarding current trading prices, EKTAF is priced at $6.20, while SRTOY trades at $21.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SRTOY's P/E ratio is 67.72. In terms of profitability, EKTAF's ROE is -0.00%, compared to SRTOY's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to SRTOY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SRTOY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, ESLOY has a market cap of 111.1B. Regarding current trading prices, EKTAF is priced at $6.20, while ESLOY trades at $120.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas ESLOY's P/E ratio is 41.34. In terms of profitability, EKTAF's ROE is -0.00%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to ESLOY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check ESLOY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, ESLOF has a market cap of 110.8B. Regarding current trading prices, EKTAF is priced at $6.20, while ESLOF trades at $239.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas ESLOF's P/E ratio is 41.04. In terms of profitability, EKTAF's ROE is -0.00%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to ESLOF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check ESLOF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, MECNY has a market cap of 107.5B. Regarding current trading prices, EKTAF is priced at $6.20, while MECNY trades at $88.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas MECNY's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to MECNY's ROE of +0.02%. Regarding short-term risk, EKTAF and MECNY have similar daily volatility (0.00).Check MECNY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SOAGY has a market cap of 78.4B. Regarding current trading prices, EKTAF is priced at $6.20, while SOAGY trades at $53.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SOAGY's P/E ratio is 103.15. In terms of profitability, EKTAF's ROE is -0.00%, compared to SOAGY's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to SOAGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SOAGY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, HOCPY has a market cap of 63.3B. Regarding current trading prices, EKTAF is priced at $6.20, while HOCPY trades at $187.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas HOCPY's P/E ratio is 49.05. In terms of profitability, EKTAF's ROE is -0.00%, compared to HOCPY's ROE of +0.25%. Regarding short-term risk, EKTAF is less volatile compared to HOCPY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check HOCPY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, HOCPF has a market cap of 62.3B. Regarding current trading prices, EKTAF is priced at $6.20, while HOCPF trades at $185.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas HOCPF's P/E ratio is 48.30. In terms of profitability, EKTAF's ROE is -0.00%, compared to HOCPF's ROE of +0.25%. Regarding short-term risk, EKTAF and HOCPF have similar daily volatility (0.00).Check HOCPF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, RSMDF has a market cap of 36.3B. Regarding current trading prices, EKTAF is priced at $6.20, while RSMDF trades at $24.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas RSMDF's P/E ratio is 24.64. In terms of profitability, EKTAF's ROE is -0.00%, compared to RSMDF's ROE of +0.25%. Regarding short-term risk, EKTAF is less volatile compared to RSMDF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check RSMDF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SDMHF has a market cap of 21.4B. Regarding current trading prices, EKTAF is priced at $6.20, while SDMHF trades at $220.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SDMHF's P/E ratio is 68.81. In terms of profitability, EKTAF's ROE is -0.00%, compared to SDMHF's ROE of +0.07%. Regarding short-term risk, EKTAF and SDMHF have similar daily volatility (0.00).Check SDMHF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, TRUMY has a market cap of 20.2B. Regarding current trading prices, EKTAF is priced at $6.20, while TRUMY trades at $13.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas TRUMY's P/E ratio is 24.41. In terms of profitability, EKTAF's ROE is -0.00%, compared to TRUMY's ROE of +0.09%. Regarding short-term risk, EKTAF is less volatile compared to TRUMY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TRUMY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SAUHF has a market cap of 18.5B. Regarding current trading prices, EKTAF is priced at $6.20, while SAUHF trades at $115.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SAUHF's P/E ratio is 41.08. In terms of profitability, EKTAF's ROE is -0.00%, compared to SAUHF's ROE of +0.17%. Regarding short-term risk, EKTAF and SAUHF have similar daily volatility (0.00).Check SAUHF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, TRUMF has a market cap of 18.3B. Regarding current trading prices, EKTAF is priced at $6.20, while TRUMF trades at $12.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas TRUMF's P/E ratio is 22.14. In terms of profitability, EKTAF's ROE is -0.00%, compared to TRUMF's ROE of +0.09%. Regarding short-term risk, EKTAF is less volatile compared to TRUMF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TRUMF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SAUHY has a market cap of 17.9B. Regarding current trading prices, EKTAF is priced at $6.20, while SAUHY trades at $11.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SAUHY's P/E ratio is 38.71. In terms of profitability, EKTAF's ROE is -0.00%, compared to SAUHY's ROE of +0.17%. Regarding short-term risk, EKTAF is less volatile compared to SAUHY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SAUHY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SUVPF has a market cap of 16.9B. Regarding current trading prices, EKTAF is priced at $6.20, while SUVPF trades at $244.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SUVPF's P/E ratio is 93.32. In terms of profitability, EKTAF's ROE is -0.00%, compared to SUVPF's ROE of +0.06%. Regarding short-term risk, EKTAF and SUVPF have similar daily volatility (0.00).Check SUVPF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SARTF has a market cap of 15.6B. Regarding current trading prices, EKTAF is priced at $6.20, while SARTF trades at $226.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SARTF's P/E ratio is 86.06. In terms of profitability, EKTAF's ROE is -0.00%, compared to SARTF's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to SARTF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SARTF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, CLPBY has a market cap of 15.2B. Regarding current trading prices, EKTAF is priced at $6.20, while CLPBY trades at $6.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas CLPBY's P/E ratio is 24.14. In terms of profitability, EKTAF's ROE is -0.00%, compared to CLPBY's ROE of +0.25%. Regarding short-term risk, EKTAF is less volatile compared to CLPBY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CLPBY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SSSGY has a market cap of 14.5B. Regarding current trading prices, EKTAF is priced at $6.20, while SSSGY trades at $42.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SSSGY's P/E ratio is 80.96. In terms of profitability, EKTAF's ROE is -0.00%, compared to SSSGY's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to SSSGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SSSGY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, CLPBF has a market cap of 13.5B. Regarding current trading prices, EKTAF is priced at $6.20, while CLPBF trades at $65.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas CLPBF's P/E ratio is 23.66. In terms of profitability, EKTAF's ROE is -0.00%, compared to CLPBF's ROE of +0.25%. Regarding short-term risk, EKTAF is less volatile compared to CLPBF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CLPBF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, FSPKF has a market cap of 13.5B. Regarding current trading prices, EKTAF is priced at $6.20, while FSPKF trades at $23.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas FSPKF's P/E ratio is 52.32. In terms of profitability, EKTAF's ROE is -0.00%, compared to FSPKF's ROE of +0.30%. Regarding short-term risk, EKTAF and FSPKF have similar daily volatility (0.00).Check FSPKF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, OCPNF has a market cap of 10.4B. Regarding current trading prices, EKTAF is priced at $6.20, while OCPNF trades at $9.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas OCPNF's P/E ratio is 17.57. In terms of profitability, EKTAF's ROE is -0.00%, compared to OCPNF's ROE of +0.11%. Regarding short-term risk, EKTAF is less volatile compared to OCPNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check OCPNF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, CNVVY has a market cap of 6.3B. Regarding current trading prices, EKTAF is priced at $6.20, while CNVVY trades at $12.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas CNVVY's P/E ratio is 38.03. In terms of profitability, EKTAF's ROE is -0.00%, compared to CNVVY's ROE of +0.10%. Regarding short-term risk, EKTAF is less volatile compared to CNVVY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CNVVY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, CNVVF has a market cap of 6.3B. Regarding current trading prices, EKTAF is priced at $6.20, while CNVVF trades at $3.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas CNVVF's P/E ratio is 35.78. In terms of profitability, EKTAF's ROE is -0.00%, compared to CNVVF's ROE of +0.11%. Regarding short-term risk, EKTAF is less volatile compared to CNVVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CNVVF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, AHICF has a market cap of 5.7B. Regarding current trading prices, EKTAF is priced at $6.20, while AHICF trades at $21.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas AHICF's P/E ratio is 51.48. In terms of profitability, EKTAF's ROE is -0.00%, compared to AHICF's ROE of +0.12%. Regarding short-term risk, EKTAF is less volatile compared to AHICF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check AHICF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SSMXY has a market cap of 5.5B. Regarding current trading prices, EKTAF is priced at $6.20, while SSMXY trades at $8.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SSMXY's P/E ratio is 18.79. In terms of profitability, EKTAF's ROE is -0.00%, compared to SSMXY's ROE of +0.09%. Regarding short-term risk, EKTAF is less volatile compared to SSMXY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SSMXY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SSMXF has a market cap of 5.3B. Regarding current trading prices, EKTAF is priced at $6.20, while SSMXF trades at $8.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SSMXF's P/E ratio is 17.94. In terms of profitability, EKTAF's ROE is -0.00%, compared to SSMXF's ROE of +0.09%. Regarding short-term risk, EKTAF is less volatile compared to SSMXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SSMXF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, ADDLF has a market cap of 4.9B. Regarding current trading prices, EKTAF is priced at $6.20, while ADDLF trades at $42.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas ADDLF's P/E ratio is 61.76. In terms of profitability, EKTAF's ROE is -0.00%, compared to ADDLF's ROE of +0.11%. Regarding short-term risk, EKTAF is less volatile compared to ADDLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check ADDLF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, YPHDF has a market cap of 4.8B. Regarding current trading prices, EKTAF is priced at $6.20, while YPHDF trades at $354.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas YPHDF's P/E ratio is 19.76. In terms of profitability, EKTAF's ROE is -0.00%, compared to YPHDF's ROE of +0.27%. Regarding short-term risk, EKTAF is less volatile compared to YPHDF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check YPHDF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, FLMNF has a market cap of 4.3B. Regarding current trading prices, EKTAF is priced at $6.20, while FLMNF trades at $50.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas FLMNF's P/E ratio is 20.06. In terms of profitability, EKTAF's ROE is -0.00%, compared to FLMNF's ROE of +0.20%. Regarding short-term risk, EKTAF is less volatile compared to FLMNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check FLMNF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, FLMNY has a market cap of 4.2B. Regarding current trading prices, EKTAF is priced at $6.20, while FLMNY trades at $9.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas FLMNY's P/E ratio is 19.48. In terms of profitability, EKTAF's ROE is -0.00%, compared to FLMNY's ROE of +0.20%. Regarding short-term risk, EKTAF is less volatile compared to FLMNY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check FLMNY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, ANSLF has a market cap of 3.3B. Regarding current trading prices, EKTAF is priced at $6.20, while ANSLF trades at $22.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas ANSLF's P/E ratio is 32.49. In terms of profitability, EKTAF's ROE is -0.00%, compared to ANSLF's ROE of +0.07%. Regarding short-term risk, EKTAF and ANSLF have similar daily volatility (0.00).Check ANSLF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, ANSLY has a market cap of 3B. Regarding current trading prices, EKTAF is priced at $6.20, while ANSLY trades at $83.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas ANSLY's P/E ratio is 22.45. In terms of profitability, EKTAF's ROE is -0.00%, compared to ANSLY's ROE of +0.07%. Regarding short-term risk, EKTAF is less volatile compared to ANSLY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check ANSLY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, CZMWY has a market cap of 2.8B. Regarding current trading prices, EKTAF is priced at $6.20, while CZMWY trades at $31.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas CZMWY's P/E ratio is 16.95. In terms of profitability, EKTAF's ROE is -0.00%, compared to CZMWY's ROE of +0.06%. Regarding short-term risk, EKTAF is less volatile compared to CZMWY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CZMWY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, CZMWF has a market cap of 2.8B. Regarding current trading prices, EKTAF is priced at $6.20, while CZMWF trades at $31.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas CZMWF's P/E ratio is 16.93. In terms of profitability, EKTAF's ROE is -0.00%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, EKTAF is less volatile compared to CZMWF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CZMWF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SHWGY has a market cap of 2.5B. Regarding current trading prices, EKTAF is priced at $6.20, while SHWGY trades at $2.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SHWGY's P/E ratio is 10.95. In terms of profitability, EKTAF's ROE is -0.00%, compared to SHWGY's ROE of +0.07%. Regarding short-term risk, EKTAF is less volatile compared to SHWGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SHWGY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, EKTAY has a market cap of 2.3B. Regarding current trading prices, EKTAF is priced at $6.20, while EKTAY trades at $6.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas EKTAY's P/E ratio is -604.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to EKTAY's ROE of -0.00%. Regarding short-term risk, EKTAF and EKTAY have similar daily volatility (0.00).Check EKTAY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, TCGGY has a market cap of 2.3B. Regarding current trading prices, EKTAF is priced at $6.20, while TCGGY trades at $36.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas TCGGY's P/E ratio is 27.27. In terms of profitability, EKTAF's ROE is -0.00%, compared to TCGGY's ROE of -0.09%. Regarding short-term risk, EKTAF is less volatile compared to TCGGY. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TCGGY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SHWGF has a market cap of 2B. Regarding current trading prices, EKTAF is priced at $6.20, while SHWGF trades at $0.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SHWGF's P/E ratio is 9.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to SHWGF's ROE of +0.07%. Regarding short-term risk, EKTAF is less volatile compared to SHWGF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SHWGF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, TCHBF has a market cap of 2B. Regarding current trading prices, EKTAF is priced at $6.20, while TCHBF trades at $156.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas TCHBF's P/E ratio is -14.12. In terms of profitability, EKTAF's ROE is -0.00%, compared to TCHBF's ROE of -0.09%. Regarding short-term risk, EKTAF and TCHBF have similar daily volatility (0.00).Check TCHBF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, BOEUF has a market cap of 1.6B. Regarding current trading prices, EKTAF is priced at $6.20, while BOEUF trades at $24.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas BOEUF's P/E ratio is 108.52. In terms of profitability, EKTAF's ROE is -0.00%, compared to BOEUF's ROE of +0.18%. Regarding short-term risk, EKTAF is less volatile compared to BOEUF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check BOEUF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, NPRRF has a market cap of 1.6B. Regarding current trading prices, EKTAF is priced at $6.20, while NPRRF trades at $9.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas NPRRF's P/E ratio is 26.92. In terms of profitability, EKTAF's ROE is -0.00%, compared to NPRRF's ROE of N/A. Regarding short-term risk, EKTAF is less volatile compared to NPRRF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check NPRRF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, TGLVY has a market cap of 1.5B. Regarding current trading prices, EKTAF is priced at $6.20, while TGLVY trades at $0.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas TGLVY's P/E ratio is 38.43. In terms of profitability, EKTAF's ROE is -0.00%, compared to TGLVY's ROE of +0.03%. Regarding short-term risk, EKTAF and TGLVY have similar daily volatility (0.00).Check TGLVY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SAFLY has a market cap of 1.3B. Regarding current trading prices, EKTAF is priced at $6.20, while SAFLY trades at $4.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SAFLY's P/E ratio is 16.22. In terms of profitability, EKTAF's ROE is -0.00%, compared to SAFLY's ROE of +0.12%. Regarding short-term risk, EKTAF and SAFLY have similar daily volatility (0.00).Check SAFLY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, BITGF has a market cap of 1.2B. Regarding current trading prices, EKTAF is priced at $6.20, while BITGF trades at $15.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas BITGF's P/E ratio is 45.50. In terms of profitability, EKTAF's ROE is -0.00%, compared to BITGF's ROE of +0.04%. Regarding short-term risk, EKTAF is less volatile compared to BITGF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check BITGF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, PBHDF has a market cap of 1.2B. Regarding current trading prices, EKTAF is priced at $6.20, while PBHDF trades at $19.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, EKTAF's ROE is -0.00%, compared to PBHDF's ROE of +0.07%. Regarding short-term risk, EKTAF and PBHDF have similar daily volatility (0.00).Check PBHDF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, TDVXF has a market cap of 1B. Regarding current trading prices, EKTAF is priced at $6.20, while TDVXF trades at $9.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas TDVXF's P/E ratio is 57.65. In terms of profitability, EKTAF's ROE is -0.00%, compared to TDVXF's ROE of +0.32%. Regarding short-term risk, EKTAF is less volatile compared to TDVXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TDVXF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SAFLF has a market cap of 906.6M. Regarding current trading prices, EKTAF is priced at $6.20, while SAFLF trades at $2.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SAFLF's P/E ratio is 16.50. In terms of profitability, EKTAF's ROE is -0.00%, compared to SAFLF's ROE of +0.12%. Regarding short-term risk, EKTAF and SAFLF have similar daily volatility (0.00).Check SAFLF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, NNCSF has a market cap of 849.5M. Regarding current trading prices, EKTAF is priced at $6.20, while NNCSF trades at $2.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas NNCSF's P/E ratio is 56.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to NNCSF's ROE of +0.10%. Regarding short-term risk, EKTAF and NNCSF have similar daily volatility (0.00).Check NNCSF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, KSRBF has a market cap of 841.7M. Regarding current trading prices, EKTAF is priced at $6.20, while KSRBF trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas KSRBF's P/E ratio is 33.29. In terms of profitability, EKTAF's ROE is -0.00%, compared to KSRBF's ROE of +0.04%. Regarding short-term risk, EKTAF and KSRBF have similar daily volatility (0.00).Check KSRBF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, HGYMF has a market cap of 754.4M. Regarding current trading prices, EKTAF is priced at $6.20, while HGYMF trades at $34.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas HGYMF's P/E ratio is 184.16. In terms of profitability, EKTAF's ROE is -0.00%, compared to HGYMF's ROE of +0.00%. Regarding short-term risk, EKTAF is less volatile compared to HGYMF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check HGYMF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, GRRMF has a market cap of 713.3M. Regarding current trading prices, EKTAF is priced at $6.20, while GRRMF trades at $20.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas GRRMF's P/E ratio is 26.14. In terms of profitability, EKTAF's ROE is -0.00%, compared to GRRMF's ROE of +0.02%. Regarding short-term risk, EKTAF is less volatile compared to GRRMF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check GRRMF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, JNDOF has a market cap of 531M. Regarding current trading prices, EKTAF is priced at $6.20, while JNDOF trades at $22.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas JNDOF's P/E ratio is 47.40. In terms of profitability, EKTAF's ROE is -0.00%, compared to JNDOF's ROE of +0.29%. Regarding short-term risk, EKTAF and JNDOF have similar daily volatility (0.00).Check JNDOF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SPMXF has a market cap of 458.6M. Regarding current trading prices, EKTAF is priced at $6.20, while SPMXF trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SPMXF's P/E ratio is -15.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to SPMXF's ROE of -0.07%. Regarding short-term risk, EKTAF is less volatile compared to SPMXF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check SPMXF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, CLHLF has a market cap of 365.5M. Regarding current trading prices, EKTAF is priced at $6.20, while CLHLF trades at $61.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas CLHLF's P/E ratio is 27.93. In terms of profitability, EKTAF's ROE is -0.00%, compared to CLHLF's ROE of +0.16%. Regarding short-term risk, EKTAF and CLHLF have similar daily volatility (0.00).Check CLHLF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, GUERF has a market cap of 281M. Regarding current trading prices, EKTAF is priced at $6.20, while GUERF trades at $22.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas GUERF's P/E ratio is 8.19. In terms of profitability, EKTAF's ROE is -0.00%, compared to GUERF's ROE of +0.04%. Regarding short-term risk, EKTAF and GUERF have similar daily volatility (0.00).Check GUERF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, TSNLF has a market cap of 249.2M. Regarding current trading prices, EKTAF is priced at $6.20, while TSNLF trades at $5.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas TSNLF's P/E ratio is 23.64. In terms of profitability, EKTAF's ROE is -0.00%, compared to TSNLF's ROE of +0.24%. Regarding short-term risk, EKTAF is less volatile compared to TSNLF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TSNLF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, OPSSF has a market cap of 247.4M. Regarding current trading prices, EKTAF is priced at $6.20, while OPSSF trades at $2.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, EKTAF's ROE is -0.00%, compared to OPSSF's ROE of -0.36%. Regarding short-term risk, EKTAF is less volatile compared to OPSSF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check OPSSF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, EEOIF has a market cap of 63.4M. Regarding current trading prices, EKTAF is priced at $6.20, while EEOIF trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, EKTAF's ROE is -0.00%, compared to EEOIF's ROE of N/A. Regarding short-term risk, EKTAF and EEOIF have similar daily volatility (0.00).Check EEOIF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, OTCFF has a market cap of 24.5M. Regarding current trading prices, EKTAF is priced at $6.20, while OTCFF trades at $0.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas OTCFF's P/E ratio is -15.32. In terms of profitability, EKTAF's ROE is -0.00%, compared to OTCFF's ROE of +1.24%. Regarding short-term risk, EKTAF is less volatile compared to OTCFF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check OTCFF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, UEEC has a market cap of 14.2M. Regarding current trading prices, EKTAF is priced at $6.20, while UEEC trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas UEEC's P/E ratio is -2.75. In terms of profitability, EKTAF's ROE is -0.00%, compared to UEEC's ROE of +1.00%. Regarding short-term risk, EKTAF is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check UEEC's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, BLMHF has a market cap of 5.2M. Regarding current trading prices, EKTAF is priced at $6.20, while BLMHF trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, EKTAF's ROE is -0.00%, compared to BLMHF's ROE of N/A. Regarding short-term risk, EKTAF and BLMHF have similar daily volatility (0.00).Check BLMHF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, PXMVF has a market cap of 4.6M. Regarding current trading prices, EKTAF is priced at $6.20, while PXMVF trades at $1.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, EKTAF's ROE is -0.00%, compared to PXMVF's ROE of -6.46%. Regarding short-term risk, EKTAF is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check PXMVF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, CBSC has a market cap of 4.5M. Regarding current trading prices, EKTAF is priced at $6.20, while CBSC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas CBSC's P/E ratio is -4.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to CBSC's ROE of +0.58%. Regarding short-term risk, EKTAF and CBSC have similar daily volatility (0.00).Check CBSC's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, MCDA has a market cap of 4.2M. Regarding current trading prices, EKTAF is priced at $6.20, while MCDA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas MCDA's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to MCDA's ROE of N/A. Regarding short-term risk, EKTAF and MCDA have similar daily volatility (0.00).Check MCDA's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, GVDI has a market cap of 4.2M. Regarding current trading prices, EKTAF is priced at $6.20, while GVDI trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas GVDI's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, EKTAF and GVDI have similar daily volatility (0.00).Check GVDI's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, RSCF has a market cap of 4.2M. Regarding current trading prices, EKTAF is priced at $6.20, while RSCF trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas RSCF's P/E ratio is -4.88. In terms of profitability, EKTAF's ROE is -0.00%, compared to RSCF's ROE of +0.10%. Regarding short-term risk, EKTAF is less volatile compared to RSCF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check RSCF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, NSTGQ has a market cap of 3.3M. Regarding current trading prices, EKTAF is priced at $6.20, while NSTGQ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, EKTAF is less volatile compared to NSTGQ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check NSTGQ's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, TUTH has a market cap of 1.7M. Regarding current trading prices, EKTAF is priced at $6.20, while TUTH trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas TUTH's P/E ratio is -0.69. In terms of profitability, EKTAF's ROE is -0.00%, compared to TUTH's ROE of +0.27%. Regarding short-term risk, EKTAF is less volatile compared to TUTH. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TUTH's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, ECIA has a market cap of 1.6M. Regarding current trading prices, EKTAF is priced at $6.20, while ECIA trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas ECIA's P/E ratio is -4.33. In terms of profitability, EKTAF's ROE is -0.00%, compared to ECIA's ROE of -0.22%. Regarding short-term risk, EKTAF and ECIA have similar daily volatility (0.00).Check ECIA's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, YBGJ has a market cap of 1.1M. Regarding current trading prices, EKTAF is priced at $6.20, while YBGJ trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas YBGJ's P/E ratio is -0.95. In terms of profitability, EKTAF's ROE is -0.00%, compared to YBGJ's ROE of +0.38%. Regarding short-term risk, EKTAF and YBGJ have similar daily volatility (0.00).Check YBGJ's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, OJSY has a market cap of 454.3K. Regarding current trading prices, EKTAF is priced at $6.20, while OJSY trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas OJSY's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to OJSY's ROE of N/A. Regarding short-term risk, EKTAF and OJSY have similar daily volatility (0.00).Check OJSY's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, PDMI has a market cap of 324.9K. Regarding current trading prices, EKTAF is priced at $6.20, while PDMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas PDMI's P/E ratio is -0.01. In terms of profitability, EKTAF's ROE is -0.00%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, EKTAF and PDMI have similar daily volatility (0.00).Check PDMI's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, WHSI has a market cap of 182.7K. Regarding current trading prices, EKTAF is priced at $6.20, while WHSI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas WHSI's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, EKTAF and WHSI have similar daily volatility (0.00).Check WHSI's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, BLFE has a market cap of 156.7K. Regarding current trading prices, EKTAF is priced at $6.20, while BLFE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas BLFE's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to BLFE's ROE of +3.67%. Regarding short-term risk, EKTAF and BLFE have similar daily volatility (0.00).Check BLFE's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, QTXB has a market cap of 118K. Regarding current trading prices, EKTAF is priced at $6.20, while QTXB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas QTXB's P/E ratio is -0.05. In terms of profitability, EKTAF's ROE is -0.00%, compared to QTXB's ROE of +0.19%. Regarding short-term risk, EKTAF is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check QTXB's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, CEOS has a market cap of 111.8K. Regarding current trading prices, EKTAF is priced at $6.20, while CEOS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas CEOS's P/E ratio is -0.01. In terms of profitability, EKTAF's ROE is -0.00%, compared to CEOS's ROE of +0.40%. Regarding short-term risk, EKTAF is less volatile compared to CEOS. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check CEOS's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, IMTH has a market cap of 89.8K. Regarding current trading prices, EKTAF is priced at $6.20, while IMTH trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas IMTH's P/E ratio is -0.03. In terms of profitability, EKTAF's ROE is -0.00%, compared to IMTH's ROE of -0.60%. Regarding short-term risk, EKTAF is less volatile compared to IMTH. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check IMTH's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, LANZ has a market cap of 74.5K. Regarding current trading prices, EKTAF is priced at $6.20, while LANZ trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas LANZ's P/E ratio is 2.70. In terms of profitability, EKTAF's ROE is -0.00%, compared to LANZ's ROE of +0.01%. Regarding short-term risk, EKTAF is less volatile compared to LANZ. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check LANZ's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, GMVDF has a market cap of 26K. Regarding current trading prices, EKTAF is priced at $6.20, while GMVDF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas GMVDF's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to GMVDF's ROE of +3.68%. Regarding short-term risk, EKTAF and GMVDF have similar daily volatility (0.00).Check GMVDF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, REMI has a market cap of 14K. Regarding current trading prices, EKTAF is priced at $6.20, while REMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas REMI's P/E ratio is -0.07. In terms of profitability, EKTAF's ROE is -0.00%, compared to REMI's ROE of -0.11%. Regarding short-term risk, EKTAF is less volatile compared to REMI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check REMI's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SDCCQ has a market cap of 13.4K. Regarding current trading prices, EKTAF is priced at $6.20, while SDCCQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, EKTAF and SDCCQ have similar daily volatility (0.00).Check SDCCQ's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, MDIT has a market cap of 8.7K. Regarding current trading prices, EKTAF is priced at $6.20, while MDIT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas MDIT's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, EKTAF and MDIT have similar daily volatility (0.00).Check MDIT's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, ASFX has a market cap of 7K. Regarding current trading prices, EKTAF is priced at $6.20, while ASFX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas ASFX's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, EKTAF is less volatile compared to ASFX. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check ASFX's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, DGEN has a market cap of 3.9K. Regarding current trading prices, EKTAF is priced at $6.20, while DGEN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas DGEN's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to DGEN's ROE of +0.05%. Regarding short-term risk, EKTAF and DGEN have similar daily volatility (0.00).Check DGEN's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SVSO has a market cap of 2.6K. Regarding current trading prices, EKTAF is priced at $6.20, while SVSO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SVSO's P/E ratio is -0.01. In terms of profitability, EKTAF's ROE is -0.00%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, EKTAF and SVSO have similar daily volatility (0.00).Check SVSO's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, LFPI has a market cap of 2.1K. Regarding current trading prices, EKTAF is priced at $6.20, while LFPI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas LFPI's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, EKTAF is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check LFPI's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, INND has a market cap of 1.5K. Regarding current trading prices, EKTAF is priced at $6.20, while INND trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas INND's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to INND's ROE of +0.09%. Regarding short-term risk, EKTAF is less volatile compared to INND. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check INND's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SEYE has a market cap of 1.2K. Regarding current trading prices, EKTAF is priced at $6.20, while SEYE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SEYE's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to SEYE's ROE of N/A. Regarding short-term risk, EKTAF and SEYE have similar daily volatility (0.00).Check SEYE's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, BGMD has a market cap of 1.1K. Regarding current trading prices, EKTAF is priced at $6.20, while BGMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas BGMD's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to BGMD's ROE of +7.47%. Regarding short-term risk, EKTAF and BGMD have similar daily volatility (0.00).Check BGMD's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, ADLI has a market cap of 1K. Regarding current trading prices, EKTAF is priced at $6.20, while ADLI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas ADLI's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, EKTAF is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check ADLI's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, VSMD has a market cap of 802. Regarding current trading prices, EKTAF is priced at $6.20, while VSMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas VSMD's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, EKTAF is less volatile compared to VSMD. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check VSMD's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, TEVNF has a market cap of 744. Regarding current trading prices, EKTAF is priced at $6.20, while TEVNF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas TEVNF's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, EKTAF is less volatile compared to TEVNF. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check TEVNF's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, HRAL has a market cap of 347. Regarding current trading prices, EKTAF is priced at $6.20, while HRAL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas HRAL's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to HRAL's ROE of +0.21%. Regarding short-term risk, EKTAF is less volatile compared to HRAL. This indicates potentially lower risk in terms of short-term price fluctuations for EKTAF.Check HRAL's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, MICRD has a market cap of 317. Regarding current trading prices, EKTAF is priced at $6.20, while MICRD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas MICRD's P/E ratio is -0.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, EKTAF and MICRD have similar daily volatility (0.00).Check MICRD's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, RGBOQ has a market cap of 97. Regarding current trading prices, EKTAF is priced at $6.20, while RGBOQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, EKTAF and RGBOQ have similar daily volatility (0.00).Check RGBOQ's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, SECI has a market cap of 31. Regarding current trading prices, EKTAF is priced at $6.20, while SECI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas SECI's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to SECI's ROE of -0.00%. Regarding short-term risk, EKTAF and SECI have similar daily volatility (0.00).Check SECI's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, VTEQ has a market cap of 1. Regarding current trading prices, EKTAF is priced at $6.20, while VTEQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, EKTAF's ROE is -0.00%, compared to VTEQ's ROE of N/A. Regarding short-term risk, EKTAF and VTEQ have similar daily volatility (0.00).Check VTEQ's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, MEDVD has a market cap of 0. Regarding current trading prices, EKTAF is priced at $6.20, while MEDVD trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas MEDVD's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to MEDVD's ROE of N/A. Regarding short-term risk, EKTAF and MEDVD have similar daily volatility (0.00).Check MEDVD's competition here

EKTAF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKTAF stands at 2.3B. In comparison, OCPNY has a market cap of 0. Regarding current trading prices, EKTAF is priced at $6.20, while OCPNY trades at $18.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKTAF currently has a P/E ratio of -620.00, whereas OCPNY's P/E ratio is N/A. In terms of profitability, EKTAF's ROE is -0.00%, compared to OCPNY's ROE of +0.26%. Regarding short-term risk, EKTAF and OCPNY have similar daily volatility (0.00).Check OCPNY's competition here